GlobalData on MSN2d
Regeneron’s Dupixent approved as first adolescent CRSwNP treatmentThe safety profile of Dupixent in adolescents with moderate-to-severe asthma contributed to the FDA's decision.
Regeneron Pharmaceuticals’ investigational melanoma combination therapy shows continued response after two years in a Phase I trial. The company presented longer-term data from the Phase I trial ...
In the Phase I trial, the duration of response to Regeneron's combination therapy continued beyond two years in melanoma ...
1d
Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Regeneron (REGN – Research Report) and keeping the price target at ...
In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Sell rating on Regeneron (REGN – Research ...
This was the stock's second consecutive day of losses.
This was the stock's fourth consecutive day of losses.
Sanofi and Regeneron’s blockbuster drug Dupixent successfully treated patients with an inflammatory skin disease in a ...
Sanofi and Regeneron’s superstar anti-inflammatory biologic Dupixent is on a roll. | It was a busy day for Sanofi and ...
Regeneron is back with long-term follow-up for its LAG-3 inhibitor and PD-1 inhibitor combo in advanced melanoma, phase 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback